Sachie Ono
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sachie Ono has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Keita Terui
Division of Pediatric Surgery, Department of Surgery, Jichi Medical University, Tochigi, Japan
3 shared publications Ayako Takenouchi
Department of Pediatric Surgery, Kimitsu Chuo Hospital, Kisarazu City, Chiba, Japan
1 shared publicationElena Terui
Department of Pediatric Surgery, Kimitsu Chuo Hospital, Kisarazu City, Chiba, Japan
1 shared publication- Hideki Enomoto
Division of Neural Differentiation and Regeneration, Department of Physiology and Cell Biology Kobe University Graduate School of Medicine Kobe Japan
1 shared publication Hideo Yoshida
Department of Pediatric Surgery, Graduate School of Medicine, Chiba University, Chiba City, Chiba, Japan
1 shared publication- Hideo Yoshida
Department of Pediatric Surgery, Graduate School of Medicine, Chiba University
1 shared publication
Latest Publications
- 14 September 2019
- Published by Wiley in Pediatrics International
- Vol. 61 (11) , 1151-1154
Risk factors for unsuccessful atropine therapy in hypertrophic pyloric stenosis
Background Intravenous atropine (IA) for infantile hypertrophic pyloric stenosis (IHPS) is a good alternative to pyloromyotomy but has not been broadly accepted. The lower success rate is one of the greatest disadvantages of IA. We aimed to investigate the risk factors for unsuccessful results following IA for IHPS. Methods Medical records of patients with IHPS who were admitted to our institution between 2002 and 2016 and were initially administered atropine sulfate were retrospectively reviewed. Atropine was given intravenously (0.1 mg/kg/day in 8 divided doses). Oral feeding of milk was started with a small amount and increased in a stepwise fashion to full feed. IA therapy was judged unsuccessful from the presence of projectile vomiting more than three times a day or intolerance to a predetermined amount of milk. Results Among the 48 patients with IHPS, 33 patients were successfully treated with IA therapy and 15 patients needed surgical intervention. Univariate analyses showed that the risk factors for unsuccessful IA therapy were younger age, lower body weight, and shorter duration of symptoms before diagnosis. Multivariate analysis showed that an age at diagnosis of p = 0.03). Conclusions An age at diagnosis <30 days was shown to be a risk factor for unsuccessful IA therapy in IHPS. This might be considered when IA therapy is applied to neonates with IHPS.
- 14 September 2019
- Published by Wiley in Pediatrics International
- Vol. 61 (11) , 1151-1154
Risk factors for unsuccessful atropine therapy in hypertrophic pyloric stenosis
Background Intravenous atropine (IA) for infantile hypertrophic pyloric stenosis (IHPS) is a good alternative to pyloromyotomy but has not been broadly accepted. The lower success rate is one of the greatest disadvantages of IA. We aimed to investigate the risk factors for unsuccessful results following IA for IHPS. Methods Medical records of patients with IHPS who were admitted to our institution between 2002 and 2016 and were initially administered atropine sulfate were retrospectively reviewed. Atropine was given intravenously (0.1 mg/kg/day in 8 divided doses). Oral feeding of milk was started with a small amount and increased in a stepwise fashion to full feed. IA therapy was judged unsuccessful from the presence of projectile vomiting more than three times a day or intolerance to a predetermined amount of milk. Results Among the 48 patients with IHPS, 33 patients were successfully treated with IA therapy and 15 patients needed surgical intervention. Univariate analyses showed that the risk factors for unsuccessful IA therapy were younger age, lower body weight, and shorter duration of symptoms before diagnosis. Multivariate analysis showed that an age at diagnosis of p = 0.03). Conclusions An age at diagnosis <30 days was shown to be a risk factor for unsuccessful IA therapy in IHPS. This might be considered when IA therapy is applied to neonates with IHPS.
Generation of conditional ALK F1174L mutant mouse models for the study of neuroblastoma pathogenesis
Neuroblastoma, an embryonal tumor arising from the sympathetic ganglia and adrenal medulla, is among the most intractable pediatric cancers. Although a variety of genetic changes have been identified in neuroblastoma, how they contribute to its pathogenesis remains largely unclear. Recent studies have identified alterations of the anaplastic lymphoma kinase (ALK) gene in neuroblastoma; ALK F1174L (a phenylalanine‐to‐leucine substitution at codon 1174) represents one of the most frequent of these somatic mutations, and is associated with amplification of the MYCN gene, the most reliable marker for the poor survival. We engineered the mouse Alk locus so that ALK F1174L is expressed by its endogenous promoter and can be induced in a spatiotemporally controlled fashion using Cre‐loxP system. Although expression of ALK F1174L resulted in enhanced proliferation of sympathetic ganglion progenitors and increased the size of the sympathetic ganglia, it was insufficient to cause neuroblastoma. However, lethal neuroblastoma frequently developed in mice co‐expressing ALK F1174L and MYCN, even in a genetic background where MYCN alone does not cause overt tumors. These data reveal that physiological expression of ALK F1174L significantly potentiates the oncogenic ability of MYCN in vivo. Our conditional mutant mice provide a valuable platform for investigating the pathogenesis of neuroblastoma.
Generation of conditional ALK F1174L mutant mouse models for the study of neuroblastoma pathogenesis
Neuroblastoma, an embryonal tumor arising from the sympathetic ganglia and adrenal medulla, is among the most intractable pediatric cancers. Although a variety of genetic changes have been identified in neuroblastoma, how they contribute to its pathogenesis remains largely unclear. Recent studies have identified alterations of the anaplastic lymphoma kinase (ALK) gene in neuroblastoma; ALK F1174L (a phenylalanine‐to‐leucine substitution at codon 1174) represents one of the most frequent of these somatic mutations, and is associated with amplification of the MYCN gene, the most reliable marker for the poor survival. We engineered the mouse Alk locus so that ALK F1174L is expressed by its endogenous promoter and can be induced in a spatiotemporally controlled fashion using Cre‐loxP system. Although expression of ALK F1174L resulted in enhanced proliferation of sympathetic ganglion progenitors and increased the size of the sympathetic ganglia, it was insufficient to cause neuroblastoma. However, lethal neuroblastoma frequently developed in mice co‐expressing ALK F1174L and MYCN, even in a genetic background where MYCN alone does not cause overt tumors. These data reveal that physiological expression of ALK F1174L significantly potentiates the oncogenic ability of MYCN in vivo. Our conditional mutant mice provide a valuable platform for investigating the pathogenesis of neuroblastoma.
- Open Access
- 5 February 2015
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 9 (1) , 23
Hybrid video-assisted thoracoscopic surgery lobectomy of fissureless congenital cystic adenomatoid malformation: a case report.
- 5 February 2015
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 9 (1) , 23
Open AccessHybrid video-assisted thoracoscopic surgery lobectomy of fissureless congenital cystic adenomatoid malformation: a case report.